Aim Rule 26

TheraCryf is a clinical stage therapeutics company developing a new generation of innovative therapeutics in oncology and behavioural brain disorders. TheraCryf’s strategy is to generate compelling data sets with a goal of partnering its programmes with mid-size to large pharma. Please click here for further information.

TheraCryf plc is incorporated and registered in England and Wales with registered number 09246681. Its main country of operation is the United Kingdom. TheraCryf plc is subject to the UK City Code on Takeovers and Mergers.

Please click here for news notifications.

Click here to view the Articles of Association and other shareholder circulars including AGM notifications.

Major shareholdings in the Company are shown in the Investor section.

TheraCryf’s shares are quoted and traded on AIM, a market operated by the London Stock Exchange plc.  Its shares are not traded on any exchange or trading platform other than AIM.

Please click here for the details of TheraCryf’s directors.

Please click here for the directors’ responsibilities.

There are no restrictions on the transfer of securities.

Please click here for annual and half yearly reports

Nominated Adviser and Broker: Cavendish Capital Markets Limited

One Bartholomew Close, London, UKEC1A 7BL

Solicitors: Pinsent Masons LLP

Pinsent Masons LLP, 30 Crown Place, London, EC2A 4EN

Auditors: RSM UK Group LLP

Third Floor, Centenary House, 69 Wellington Street, Glasgow, G2 6HG

Patent Attorneys:

HGF Ltd

6th Floor, 4 Hardman St, Manchester M3 3HF

Potter Clarkson LLP

Chapel Quarter, Mount Street, Nottingham, NG1 6HQ

Financial Public Relations: Instinctif Partners Limited

65 Gresham Street, London, EC2V 7NQ

Registrars: Equiniti Limited

Aspect House, Spencer Road, Lancing, West Sussex, BN99 6DA

The information below has been disclosed pursuant to Rule 26 of the AIM Rules for Companies.